Literature DB >> 11913673

Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications.

Paul E Keck1, Susan L McElroy.   

Abstract

BACKGROUND: A number of medications are now available or are in development as antimanic and/or mood-stabilizing agents. We reviewed the clinical pharmacodynamics and pharmacokinetics of these agents to provide a summary of these properties relevant to clinical practice.
METHOD: We conducted a MEDLINE search augmented by a manual search of bibliographies and a review of textbooks to identify articles regarding the clinical pharmacology of lithium, valproate, carbamazepine, oxcarbazepine, olanzapine, clozapine, risperidone, ziprasidone, quetiapine, lamotrigine, and topiramate.
RESULTS: Not surprisingly, there are a number of clinically relevant pharmacodynamic and pharmacokinetic differences among these medications, and these differences are discussed.
CONCLUSION: Knowledge of the clinical pharmacology of established and putative antimanic and mood-stabilizing medications is important in administering these agents safely and effectively.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11913673

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  21 in total

Review 1.  Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management.

Authors:  Michael Levine; Anne-Michelle Ruha
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

Review 2.  Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions.

Authors:  Trino Baptista; N M K Ng Ying Kin; Serge Beaulieu
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Developing in vitro-in vivo correlation of risperidone immediate release tablet.

Authors:  Yardi Saibi; Hitoshi Sato; Hidehisa Tachiki
Journal:  AAPS PharmSciTech       Date:  2012-06-14       Impact factor: 3.246

4.  A case of priapism associated with rapid increase in risperidone dose.

Authors:  Shariq Refai; Helenna H Nakama
Journal:  Prim Care Companion CNS Disord       Date:  2012-09-20

5.  Optical drug monitoring: photoacoustic imaging of nanosensors to monitor therapeutic lithium in vivo.

Authors:  Kevin J Cash; Chiye Li; Jun Xia; Lihong V Wang; Heather A Clark
Journal:  ACS Nano       Date:  2015-01-21       Impact factor: 15.881

6.  Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles.

Authors:  Sarah Baltzley; Atiquzzaman Mohammad; Ahmad H Malkawi; Abeer M Al-Ghananeem
Journal:  AAPS PharmSciTech       Date:  2014-08-21       Impact factor: 3.246

Review 7.  Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Authors:  Kristina M Deligiannidis; Nancy Byatt; Marlene P Freeman
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

8.  The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial.

Authors:  Takeshi Tsujino; Hiroyuki Isayama; Yousuke Nakai; Yukiko Ito; Osamu Togawa; Nobuo Toda; Toshihiko Arizumi; Hirofumi Kogure; Keisuke Yamamoto; Suguru Mizuno; Yoko Yashima; Hiroshi Yagioka; Takashi Sasaki; Saburo Matsubara; Natsuyo Yamamoto; Kenji Hirano; Naoki Sasahira; Minoru Tada; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2012-10-24       Impact factor: 7.527

9.  Effect of Imipramine, Paroxetine, and Lithium Carbonate on Neurobehavioral Changes of Streptozotocin in Rats: Impact on Glycogen Synthase Kinase-3 and Blood Glucose Level.

Authors:  Rania I Nadeem; Hebatalla I Ahmed; Ezz-El-Din S El-Denshary
Journal:  Neurochem Res       Date:  2015-07-28       Impact factor: 3.996

10.  The role of lamotrigine in the management of bipolar disorder.

Authors:  Felicity Ng; Karen Hallam; Nellie Lucas; Michael Berk
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.